Table 2. Patient characteristics.
| Patients | 32 |
| Male sex | 15 (46.9%) |
| Primary disease | |
| Inflammatory bowel disease | 12 (37.5%) |
| Rheumatic disease | 10 (31.3%) |
| Kidney transplant | 4 (12.5%) |
| Liver transplant | 3 (9.4%) |
| Hepatic disease | 2 (6.3%) |
| IgA nephropathy | 1 (3.1%) |
| Number of vaccinations | 64 |
| MR vaccine | 22 (34.4%) |
| Varicella vaccine | 28 (43.8%) |
| Mumps vaccine | 14 (21.9%) |
| Number of initial vaccinations | 57 |
| MR vaccine | 21 (36.8%) |
| Varicella vaccine | 23 (40.4%) |
| Mumps vaccine | 13 (22.8%) |
| Age at vaccination (y) | 5 (1–25) |
| CD4 cell count at vaccination (/mm3) | 1104.9±414.7 |
| PHA stimulation index at vaccination | 321.4±165.2 |
| Serum IgG at vaccination (mg/dL) | 932.8±409.6 |
| Immunosuppressive agents at vaccination | |
| Calcineurin inhibitors (CsA, Tac) | 7 (10.9%) |
| Antimetabolite agents (MMF, MZR, AZP, EVR, MTX) | 41 (64.1%) |
| Calcineurin inhibitors + antimetabolite agents | 13 (20.3%) |
| Two antimetabolite agents | 3 (4.7%) |
| Steroid use at vaccination | 33 (51.6%) |
Data were shown as number (%), mean ± standard deviation or median (range).
MR, measles and rubella; PHA, phytohemagglutinin; CsA, cyclosporine; Tac, tacrolimus; MMF, mycophenolate mofetil; MZR, mizoribine; AZP, azathioprine; EVR, everolimus; MTX, methotrexate.